MMP12 and chronic obstructive pulmonary disease: Recent studies have shown that neutrophil elastase, MMP-12, and mucus production targeting neutrophil infiltration may become new therapeutic targets for COPD (References [23, 24]), while dupilumab and mepolizumab targeting eosinophilic infiltration have shown relatively good efficacy [25, 26].